Analyst firms · Morgan Stanley · INSM

Morgan Stanley INSM price target and rating history

Insmed Incorporated (INSM) · Health Care

Morgan Stanley rates Insmed Incorporated (INSM) Overweight with a $212 price target, as of its latest action on Mar 30, 2026. It has published 3 rating actions on INSM since October 2021, including 1 upgrade and 1 downgrade. Across 9 firms with a INSM price target in the last 12 months, the median target is $212. Morgan Stanley's target matches it.

Current rating
Overweight
Price target
$212
Median target, all firms
$212
Actions on INSM
3

Morgan Stanley price target on INSM

$212$132$5220222023202420252026
Morgan Stanley price target on INSM, each point a stated target, October 2021 to March 2026.

Every Morgan Stanley rating on INSM

How other firms rate INSM

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightBuy$220Nov 4, 2026
Wolfe ResearchPeer PerformOct 12, 2026
Goldman SachsBuy$188Sep 24, 2026
BMO Capital MarketsOutperform$192Jul 21, 2026
Raymond JamesOutperform$200Apr 10, 2026
Morgan StanleyOverweight$212Mar 30, 2026
JefferiesBuyMar 16, 2026
BarclaysOverweight$231Jan 28, 2026
Roth CapitalBuy$212Jan 23, 2026
Truist SecuritiesBuy$202Dec 19, 2025
Rothschild & Co RedburnBuy$263Dec 4, 2025

Questions about Morgan Stanley and INSM

What is Morgan Stanley's price target for INSM?
Morgan Stanley's latest stated price target for Insmed Incorporated (INSM) is $212, from its action on Mar 30, 2026.
What is Morgan Stanley's rating on INSM?
Morgan Stanley rates INSM Overweight, a bullish rating, as of Mar 30, 2026.
When did Morgan Stanley last change its view on INSM?
On Mar 30, 2026, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $212.
How does Morgan Stanley's INSM target compare with other analysts?
Across 9 firms with a INSM price target in the last 12 months, the median target is $212. Morgan Stanley's target matches it.

All Morgan Stanley ratingsINSM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.